Tofacitinib significantly regrows hair in severe alopecia without major side effects.
17 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.
Alopecia areata causes hair loss and needs personalized care to manage its emotional and social effects.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Adding dupilumab led to almost complete hair regrowth in a patient with alopecia areata who only partially responded to baricitinib.
15 citations
,
January 2024 in “The AAPS Journal” 50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.
June 2022 in “Frontiers in Immunology” Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.
July 2023 in “Anais Brasileiros de Dermatologia” Mesalazine showed limited effectiveness in treating children with severe alopecia areata.
20 citations
,
December 2019 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Blocking IL-12/IL-23 does not help with hair loss in alopecia areata for mice or humans.
8 citations
,
June 2022 in “Frontiers in Medicine” Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.
3 citations
,
March 2020 in “International Journal of Dermatology” Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.
1 citations
,
January 2021 PRP is effective for treating patchy alopecia areata.
January 2025 in “Dermatologic Therapy” Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.
Understanding both skin and mental health aspects of alopecia areata is crucial for better patient care.
December 2024 in “Frontiers in Pediatrics” Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.
July 2024 in “Journal of Controlled Release” Nanostructured lipid carriers effectively deliver tofacitinib to hair follicles, reversing hair loss in alopecia areata.
January 2024 in “JEADV clinical practice” The study helps doctors use patient images to understand and apply SALT scores for treating severe alopecia areata.
New drugs, baricitinib and ritlecitinib, are effective for severe alopecia areata.
Psychological factors significantly impact alopecia areata.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
13 citations
,
February 2017 in “Clinical rheumatology” Tofacitinib may help treat nail dystrophy, especially when other treatments fail.
June 2025 in “Indus journal of bioscience research.” Oral tofacitinib is more effective than oral minoxidil for treating alopecia areata.
November 2024 in “Journal of the Philippine Dermatological Society” Combining methotrexate and corticosteroids can effectively regrow hair in severe alopecia areata.
2 citations
,
September 2021 in “Curēus” Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.
22 citations
,
November 2024 in “Planta” Aromatic plants can naturally help prevent skin aging and improve skin health.
16 citations
,
October 2020 in “Lipids in Health and Disease” Leptin affects skin and hair health and may worsen some skin conditions, but more research is needed to understand its full impact.
March 2017 in “Zenodo (CERN European Organization for Nuclear Research)” L. plantarum MTCC 1325 may help improve memory and cognitive functions in Alzheimer's.
148 citations
,
December 2018 in “Journal of autoimmunity” Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.
55 citations
,
October 2019 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” The review suggests that other immune cells besides CD8+ T cells may contribute to alopecia areata and that targeting regulatory cell defects could improve treatment.